8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


FORM 8-K

 


CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2006

 


TARGACEPT, INC.

(Exact name of registrant as specified in its charter)

 


 

Delaware   000-51173   56-2020050

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

200 East First Street, Suite 300

Winston-Salem, North Carolina

    27101
(Address of principal executive offices)     (Zip Code)

(336) 480–2100

Registrant’s telephone number, including area code

 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 8.01 Other Events.

On November 9, 2006, Targacept, Inc. issued a press release announcing results of its Phase II clinical trial of mecamylamine hydrochloride as an augmentation treatment for major depression. The trial evaluated the effects of mecamylamine taken with citalopram hydrobromide, a treatment combination known as TRIDMAC™, in patients who did not respond adequately to citalopram alone. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

 

  (d) Exhibits

 

Exhibit
Number
  

Description

99.1    Press release dated November 9, 2006


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  TARGACEPT, INC.
Date: November 9, 2006  

/s/ Alan A. Musso

  Alan A. Musso
 

Vice President, Chief Financial Officer,

Secretary and Treasurer


EXHIBIT INDEX

 

Exhibit
Number
  

Description

99.1    Press release dated November 9, 2006